Matinas BioPharma Holdings, Inc. (MTNB) stock
MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.91+0.05 (+6.35%)
Close on Nov 18, 2026Market cap $13.37MP/E –Yield –
Matinas BioPharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Matinas BioPharma's free cash flow for the twelve months ending Dec 31, 2023 was -$15.50M. For fiscal 2023 it was -$15.50M. The highest annual figure on record is -$3.08M in fiscal 2013.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$15.50M | – |
| FY2022 | Dec 31, 2022 | -$20.05M | – |
| FY2021 | Dec 31, 2021 | -$15.48M | – |
| FY2020 | Dec 31, 2020 | -$17.37M | – |
| FY2019 | Dec 31, 2019 | -$14.50M | – |
| FY2018 | Dec 31, 2018 | -$10.86M | – |
| FY2017 | Dec 31, 2017 | -$12.40M | – |
| FY2016 | Dec 31, 2016 | -$6.12M | – |
| FY2015 | Dec 31, 2015 | -$7.89M | – |
| FY2014 | Dec 31, 2014 | -$8.25M | – |
| FY2013 | Dec 31, 2013 | -$3.08M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$4.58M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.44M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.34M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.22M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.19M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.30M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.99M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.97M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.31M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.23M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.17M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.67M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.90M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.15M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.41M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.04M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.62M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.91M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.42M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.91M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.03M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.82M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.12M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.37M | – |
See a number that looks wrong?